The combination of canagliflozin and omega-3 fatty acid ameliorates insulin resistance and cardiac biomarkers via modulation of inflammatory cytokines in type 2 diabetic rats.
10.4196/kjpp.2018.22.5.493
- Author:
Mohammed Mohsen SAFHI
1
;
Tarique ANWER
;
Gyas KHAN
;
Rahimullah SIDDIQUI
;
Sivagurunathan MONI SIVAKUMAR
;
Mohammad Firoz ALAM
Author Information
1. Department of Pharmacology, College of Pharmacy, Jazan University, Gizan 45142, Saudi Arabia. msafhi@jazanu.edu.sa
- Publication Type:Original Article
- Keywords:
Hyperinsulinemia;
Inflammatory cytokines;
Nicotinamide;
Streptozotocin;
Type 2 diabetes mellitus
- MeSH:
Animals;
Biomarkers*;
Canagliflozin*;
Cytokines*;
Diabetes Mellitus, Type 2;
Glucose;
Hyperinsulinism;
Insulin Resistance*;
Insulin*;
Interleukin-2;
Niacinamide;
Pancreas;
Rats*;
Streptozocin;
Troponin
- From:The Korean Journal of Physiology and Pharmacology
2018;22(5):493-501
- CountryRepublic of Korea
- Language:English
-
Abstract:
The present study was carried out with the hypothesis that combination of canagliflozin and omega-3 fatty acid may have potential effect on insulin level, insulin resistance, cardiac biomarkers, inflammatory cytokines and histological studies in type 2 diabetes mellitus (DM). Type 2 DM was induced by injecting nicotinamide (120 mg/kg, i.p.) 15 min before STZ (60 mg/kg) injection. Canagliflozin (5 and 10 mg/kg) and omega-3 fatty acid (300 mg/kg) were given for 28 days after confirmation of diabetes. Biochemical estimations revealed elevated levels of glucose, insulin, HOMA-R and inflammatory cytokines in diabetic group. Daily dosing of alone canagliflozin and omega-3 fatty acid slightly reduced elevated levels of glucose, insulin, HOMA-R and inflammatory cytokines (IL-1β, IL-2, and TNFα), whereas canagliflozin and omega-3 fatty acid combination has reduced these biochemical parameters significantly when compared with diabetic group. Similarly in diabetic group the levels of cardiac biomarkers such as lipid profile, LDH, CKMB and troponin were significantly increased. Elevated levels of cardiac biomarkers were significantly reduced after daily dosing of alone canagliflozin and omega-3 fatty acid. Canagliflozin and omega-3 fatty acid combination has offered better improvement in cardiac biomarkers compared to alone canagliflozin and omega-3 fatty acid. Histopathological analysis also supported the above hypothesis that combination therapy (canagliflozin and omega-3 fatty acid) offered better protection against degenerative changes in β-cells of pancreas as compared to alone treatment with these drugs. Thus the present study revealed that canagliflozin and omega-3 fatty acid can be used as potential combination therapy in type 2 DM along with cardiac complication.
